Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3410)	10/19/2002 12:15:27 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 10345

Bioorg Med Chem Lett 2002 Nov 4;12(21):3051 A series of C-Terminal amino alcohol dipeptide Abeta inhibitors. Garofalo A, Wone D, Phuc A, Audia J, Bales C, Dovey H, Dressen D, Folmer B, Goldbach E, Guinn A, Latimer L, Mabry T, Nissen J, Pleiss M, Sohn S, Thorsett E, Tung J, Wu J. Elan, 800 Gateway Blvd, South San Francisco, CA 94080, USA Potent, small molecule Abeta inhibitors have been prepared that incorporate an alanine core bracketed by an N-terminal arylacetyl group and various C-terminal amino alcohols. The compounds exhibit stereospecific inhibition as demonstrated in an in vitro assay.